Investors
AVEO is committed to delivering long-term value to investors through sustainable business development strategies and focused execution.
Financing to Date:
To date, AVEO has raised $169 million, including $91.5 million of non-dilutive capital in the form of license fees, milestone payments and research and development funding, through a number of strategic partnerships based on our Human Response Platform and products derived there from with leading cancer companies including Merck, OSI Pharmaceuticals, Inc., or OSI, Schering-Plough (now Merck), and Biogen Idec Inc. or Biogen Idec.
Institutional & Corporate Investors:
Bessemer Venture Partners
Biogen Idec
Flagship Ventures
GE Capital
Greylock Partners
Lotus Biosciences
MPM Capital
Merck & Company
Merlin BioMed Group
Mitsubishi UFJ Financial Group
OSI Pharmaceuticals
Oxford Bioscience Partners
Prospect Ventures
Schering-Plough Corporation
Vatera Holdings
Venrock